EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase I)Open Access · CC BY 4.0

Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers

Elisa Fabbrini iD, Anastasiya Koshkina, Michael Hackett, Michael Zhao, Kishore Thalluri, Marcus Hompesch, Alejandra Macias, Kristi Schneider iD, David A D'Alessio, Richard D DiMarchi, Salomon Azoulay

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf691 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Elisa Fabbrini und 10 weiteren Autor:innen. Beteiligte Einrichtung: MBX Biosciences, Inc., Carmel, IN 46032, USA. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MBX Biosciences, Inc., of Carmel, Indiana.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

After weight-loss surgery, some patients experience postbariatric hypoglycemia (PBH). Although PBH is customarily managed by dietary modifications with continuous glucose monitoring, advanced treatment options are needed. Imapextide is a sustained-action, selective, reversible glucagon-like peptide-1 (GLP-1) receptor antagonist designed for once-weekly administration for PBH treatment.

Objective

This work aimed to evaluate safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple ascending doses (SAD/MAD) of imapextide in healthy volunteers (HVs).

Methods

This 3-part, phase 1, double-blind study enrolled healthy adults. In the SAD/MAD parts, randomly assigned participants (3:1) received subcutaneous imapextide (SAD, 10-200 mg; MAD, 10-30 mg once weekly, 4 doses) or placebo. The primary end point was safety/tolerability (treatment-emergent adverse events [TEAEs]). PK (SAD/MAD; time-to-maximal concentration [tmax] and half-life [t1/2]) and PD (MAD; GLP-1 and glycemic parameters during a mixed meal tolerance test [MMTT]) were assessed. Imapextide drug-drug interactions (DDIs) of OATP1B1/OATP1B3 inhibition and accelerated gastric emptying were evaluated with coproporphyrin-I, rosuvastatin, and acetaminophen.

Results

Overall, 69 HVs were randomly assigned (32 SAD, 23 MAD, 14 DDIs). Imapextide TEAE rates ranged from 33.3% to 50.0% (SAD), 33.3% to 100% (MAD), and 14.3% (DDIs) across cohorts. The most common TEAEs included injection site erythema (SAD, MAD) and injection site swelling (MAD). Imapextide exposure was dose proportional (median tmax 24-48 hours; mean t1/2 ∼90 hours). During the MMTT, imapextide increased GLP-1 concentrations at early time points, while effects on other glycemic parameters were variable. Minimal nonclinically relevant DDIs occurred with rosuvastatin. Imapextide slightly accelerated gastric emptying.

Conclusion

Imapextide was generally well tolerated in HVs. PK findings supported weekly dosing. PD showed consistent effects on GLP-1 levels, supporting a potential role for imapextide in modulating PBH pathophysiology.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 ReceptorHumansMaleAdultFemaleDouble-Blind MethodHealthy VolunteersMiddle AgedYoung AdultBlood GlucoseDose-Response Relationship, DrugDelayed-Action PreparationsHypoglycemia

Stichwörter der Autor:innen

GLP-1 receptor antagonistbariatric surgeryclinical trialimapextidephase 1postbariatric hypoglycemia

Substanzen

Glucagon-Like Peptide-1 ReceptorBlood GlucoseDelayed-Action Preparations

Autor:innen und Institutionen

  • MBX Biosciences, Inc., Carmel, IN 46032, USA.
  • Department of Chemistry, Indiana University, Bloomington, IN 47405, USA.
  • ProSciento, Inc., Chula Vista, CA 91911, USA.
  • Duke Molecular Physiology Institute, Duke University, Durham, NC 27701, USA.
  • Department of Medicine, Duke University, Durham, NC 27701, USA.

ORCID-Profile: Elisa Fabbrini, Kristi Schneider

Förderung

  • MBX Biosciences, Inc., of Carmel, Indiana

Zitieren

APA

Fabbrini, E., Koshkina, A., Hackett, M., Zhao, M., Thalluri, K., Hompesch, M., Macias, A., Schneider, K., D'Alessio, D. A., DiMarchi, R. D., & Azoulay, S. (2025). Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf691

Vancouver

Fabbrini E, Koshkina A, Hackett M, Zhao M, Thalluri K, Hompesch M, et al. Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf691

BibTeX
@article{Fabbrini2025,
  author = {Fabbrini, Elisa and Koshkina, Anastasiya and Hackett, Michael and Zhao, Michael and Thalluri, Kishore and Hompesch, Marcus and Macias, Alejandra and Schneider, Kristi and D'Alessio, David A and DiMarchi, Richard D and Azoulay, Salomon},
  title = {Sustained Action of Imapextide, A Glucagon-Like Peptide-1 Receptor Antagonist, in Healthy Volunteers},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf691}
}
Kostenlos starten →